Published in J Transl Med on October 20, 2011
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2012) 1.51
NK cells: key to success of DC-based cancer vaccines? Oncologist (2012) 0.98
Biological role of NK cells and immunotherapeutic approaches in breast cancer. Front Immunol (2012) 0.87
Natural killer cells as helper cells in dendritic cell cancer vaccines. Front Immunol (2015) 0.84
Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I/II trial. Cell Mol Immunol (2014) 0.81
Dendritic Cell (DC) Vaccine in Mouse Lung Cancer Minimal Residual Model; Comparison of Monocyte-derived DC vs. Hematopoietic Stem Cell Derived-DC. Immune Netw (2012) 0.79
Mechanisms and applications of interleukins in cancer immunotherapy. Int J Mol Sci (2015) 0.78
A simple in vitro method for evaluating dendritic cell-based vaccinations. Onco Targets Ther (2014) 0.78
Pattern response of dendritic cells in the tumor microenvironment and breast cancer. World J Clin Oncol (2014) 0.76
Induced Pluripotent Stem Cell as a New Source for Cancer Immunotherapy. Genet Res Int (2016) 0.76
Treatment with cyclophosphamide supported by various dendritic cell-based vaccines induces diversification in CD4+ T cell response against MC38 colon carcinoma. Int J Oncol (2015) 0.75
Tumor heterogeneity as a rationale for a multi-epitope approach in an autologous renal cell cancer tumor vaccine. Onco Targets Ther (2016) 0.75
Immunotherapy of advanced renal cell carcinoma: Current and future therapies. Hum Vaccin Immunother (2016) 0.75
Targeting breast cancer stem cells by dendritic cell vaccination in humanized mice with breast tumor: preliminary results. Onco Targets Ther (2016) 0.75
Dendritic cells and the control of immunity. Nature (1998) 56.54
Immunobiology of dendritic cells. Annu Rev Immunol (2000) 23.65
Taking dendritic cells into medicine. Nature (2007) 11.82
The biology of human natural killer-cell subsets. Trends Immunol (2001) 10.10
Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol (2006) 6.62
Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med (2002) 4.67
Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med (2002) 4.32
Dendritic cell immunotherapy: mapping the way. Nat Med (2004) 4.28
Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med (2005) 3.70
Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med (2002) 3.35
The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol (2003) 3.06
NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood (2005) 2.31
Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol (2003) 2.17
Dendritic cells in cancer immunotherapy. Annu Rev Immunol (2000) 2.11
CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother (2005) 1.78
Dendritic cells for active immunotherapy: optimizing design and manufacture in order to develop commercially and clinically viable products. Vaccine (2007) 1.75
Dendritic cells: On the move from bench to bedside. Nat Med (2001) 1.52
Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother (2008) 1.37
Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells. Blood (2004) 1.29
A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment. Blood (2000) 1.26
Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression. J Immunol (2005) 1.18
Monitoring human blood dendritic cell numbers in normal individuals and in stem cell transplantation. Blood (1999) 1.03
Dendritic cells (DC) promote natural killer (NK) cell functions: dynamics of the human DC/NK cell cross talk. Eur Cytokine Netw (2002) 0.99
Comparison of alpha-Type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients. Vaccine (2008) 0.88
Vaccination with tumor-antigen-pulsed dendritic cells induces in vivo resistance to a B cell lymphoma. Adv Exp Med Biol (1993) 0.81
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med (2011) 12.45
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med (2015) 5.07
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med (2015) 4.97
Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science (2002) 4.72
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol (2013) 3.87
Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol (2006) 2.92
Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res (2010) 2.82
The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma. Gynecol Oncol (2011) 2.76
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol (2012) 2.48
Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial. J Clin Oncol (2013) 2.26
Obesity and prognosis in muscle-invasive bladder cancer: the continuing controversy. Int J Urol (2014) 2.06
Brain metastases in breast cancer: prognostic factors and management. Breast Cancer Res Treat (2007) 1.92
Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: oncologic safety and reproductive outcomes. Gynecol Oncol (2008) 1.89
18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO. J Nucl Med (2013) 1.82
Laparoscopic management of early uterine cancer: 10-year experience in Asan Medical Center. Gynecol Oncol (2007) 1.81
The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy. J Urol (2010) 1.80
Renal angiomyolipoma with minimal fat: differentiation from other neoplasms at double-echo chemical shift FLASH MR imaging. Radiology (2006) 1.79
Leptomeningeal carcinomatosis in gastric cancer. J Neurooncol (2004) 1.71
Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat (2007) 1.68
The impact of tumor location on prognosis of transitional cell carcinoma of the upper urinary tract. J Urol (2004) 1.62
Apc inhibition of Wnt signaling regulates supernumerary tooth formation during embryogenesis and throughout adulthood. Development (2009) 1.59
Salvage esophagectomy for locoregional failure after chemoradiotherapy in patients with advanced esophageal cancer. Ann Thorac Surg (2012) 1.56
Alternative transcription exceeds alternative splicing in generating the transcriptome diversity of cerebellar development. Genome Res (2011) 1.52
Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin. Gynecol Oncol (2012) 1.49
Followup of unilateral renal function after laparoscopic partial nephrectomy. J Urol (2011) 1.49
Prostate cancer in Korean men exhibits poor differentiation and is adversely related to prognosis after radical prostatectomy. Urology (2006) 1.47
Type II papillary histology predicts poor outcome in patients with renal cell carcinoma and vena cava thrombus. BJU Int (2012) 1.47
High percent tumor volume predicts biochemical recurrence after radical prostatectomy in pathological stage T3a prostate cancer with a negative surgical margin. Int J Urol (2013) 1.42
Effect of prostate size on pathological outcome and biochemical recurrence after radical prostatectomy for prostate cancer: is it correlated with serum testosterone level? BJU Int (2010) 1.39
Incidence, risk factors and clinical course of pancreatic fluid collections in acute pancreatitis. Dig Dis Sci (2013) 1.38
Multilocular cystic renal cell carcinoma: clinicopathological features and preoperative prediction using multiphase computed tomography. BJU Int (2011) 1.31
VDUP1 is required for the development of natural killer cells. Immunity (2005) 1.31
Synergistic antibacterial effect of curcumin against methicillin-resistant Staphylococcus aureus. Phytomedicine (2013) 1.26
Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancer. Gynecol Oncol (2007) 1.23
Histone demethylase LSD1 is required to induce skeletal muscle differentiation by regulating myogenic factors. Biochem Biophys Res Commun (2010) 1.22
The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. Jpn J Clin Oncol (2010) 1.21
The protective role of renal parenchyma as a barrier to local tumor spread of upper tract transitional cell carcinoma and its impact on patient survival. J Urol (2009) 1.19
Prospective patterns and correlates of quality of life among women in substance abuse treatment. Drug Alcohol Depend (2012) 1.18
Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. Eur J Cancer (2007) 1.16
Carbon monoxide mediates heme oxygenase 1 induction via Nrf2 activation in hepatoma cells. Biochem Biophys Res Commun (2006) 1.13
Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma. Clin Cancer Res (2013) 1.13
Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC). Breast Cancer Res Treat (2008) 1.12
Intramedullary spinal cord metastases: a single-institution experience. J Neurooncol (2007) 1.10
Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma. Chemotherapy (2013) 1.10
Predictive characteristics of malignant pheochromocytoma. Korean J Urol (2011) 1.09
Adipose-derived stem cells as a new therapeutic modality for ageing skin. Exp Dermatol (2011) 1.09
Malignant transformation of mature cystic teratoma of the ovary: experience at a single institution. Eur J Obstet Gynecol Reprod Biol (2008) 1.09
Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy. Clin Cancer Res (2008) 1.09
Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. Clin Immunol (2007) 1.08
Relationship between the integrity of the pelvic floor muscles and early recovery of continence after radical prostatectomy. J Urol (2007) 1.07
Surgical management of borderline ovarian tumors: The role of fertility-sparing surgery. Gynecol Oncol (2009) 1.06
Stage IIIC epithelial ovarian cancer classified solely by lymph node metastasis has a more favorable prognosis than other types of stage IIIC epithelial ovarian cancer. J Gynecol Oncol (2008) 1.06
A programmable microfluidic cell array for combinatorial drug screening. Lab Chip (2012) 1.06
Papillary mucinous metaplasia of the endometrium as a possible precursor of endometrial mucinous adenocarcinoma. Mod Pathol (2012) 1.06
Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989-2007. J Cancer Res Clin Oncol (2008) 1.05
Comparison of the validity of magnetic resonance imaging and positron emission tomography/computed tomography in the preoperative evaluation of patients with uterine corpus cancer. Gynecol Oncol (2008) 1.04
BIX-01294 induces autophagy-associated cell death via EHMT2/G9a dysfunction and intracellular reactive oxygen species production. Autophagy (2013) 1.04
The impact of tumor morcellation during surgery on the outcomes of patients with apparently early low-grade endometrial stromal sarcoma of the uterus. Ann Surg Oncol (2011) 1.03
Practice guidelines for the early detection of cervical cancer in Korea: Korean Society of Gynecologic Oncology and the Korean Society for Cytopathology 2012 edition. J Gynecol Oncol (2013) 1.02
Use of 18F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx. J Nucl Med (2007) 1.01
High frequency piezoelectric MEMS ultrasound transducers. IEEE Trans Ultrason Ferroelectr Freq Control (2007) 1.01
Ex vivo screening for immunodominant viral epitopes by quantitative real time polymerase chain reaction (qRT-PCR). J Transl Med (2003) 1.01
Synergistic effect of emodin in combination with ampicillin or oxacillin against methicillin-resistant Staphylococcus aureus. Pharm Biol (2010) 1.01
Significance of isoagglutinin titer in ABO-incompatible kidney transplantation. J Clin Apher (2013) 0.99
Wash-in rate on the basis of dynamic contrast-enhanced MRI: usefulness for prostate cancer detection and localization. J Magn Reson Imaging (2005) 0.99
Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy. Cancer Chemother Pharmacol (2012) 0.98
Epidemiological characteristics of ovarian cancer in Korea. J Gynecol Oncol (2010) 0.98
Is complete surgical staging necessary in patients with stage I mucinous epithelial ovarian tumors? Gynecol Oncol (2006) 0.98
Further stratification of risk groups in patients with lymph node metastasis after radical hysterectomy for early-stage cervical cancer. Gynecol Oncol (2010) 0.97
ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. Eur J Cancer (2007) 0.97
Retrievable covered nitinol stents: experiences in 108 patients with malignant esophageal strictures. J Vasc Interv Radiol (2002) 0.97
Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in patients with breast cancer following neoadjuvant chemotherapy. J Breast Cancer (2012) 0.96
Tree-based position weight matrix approach to model transcription factor binding site profiles. PLoS One (2011) 0.96
Prognostic value of lymphovascular invasion in transitional cell carcinoma of upper urinary tract. Urology (2005) 0.95
Neoadjuvant chemotherapy with paclitaxel plus platinum followed by radical surgery in early cervical cancer during pregnancy: three case reports. Jpn J Clin Oncol (2010) 0.95
Prognostic significance of perinephric fat infiltration and tumor size in renal cell carcinoma. J Urol (2008) 0.95
Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy? Urol Oncol (2011) 0.95
Laparoscopic versus open radical hysterectomy in patients with stage IB2 and IIA2 cervical cancer. J Surg Oncol (2013) 0.94
Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01). Breast Cancer Res Treat (2010) 0.94
Comparison of laparoscopy and laparotomy in surgical staging of early-stage ovarian and fallopian tubal cancer. Ann Surg Oncol (2008) 0.94
Vaginal cuff dehiscence after hysterectomy. Int J Gynaecol Obstet (2013) 0.94
Peroxiredoxin 6 overexpression attenuates cisplatin-induced apoptosis in human ovarian cancer cells. Cancer Invest (2011) 0.94
Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum. Invest New Drugs (2011) 0.94
Detection of differential proteomes associated with the development of type 2 diabetes in the Zucker rat model using the iTRAQ technique. J Proteome Res (2010) 0.93
Finding and characterizing mammary analogue secretory carcinoma of the salivary gland. Korean J Pathol (2013) 0.93
Surgical staging and adjuvant chemotherapy in the management of patients with adult granulosa cell tumors of the ovary. Gynecol Oncol (2011) 0.93
Therapeutic effects of resveratrol during acute periods following experimental ischemic stroke. J Neuroimmunol (2010) 0.93
Comparison of outcomes between radical hysterectomy followed by tailored adjuvant therapy versus primary chemoradiation therapy in IB2 and IIA2 cervical cancer. J Gynecol Oncol (2012) 0.93
Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression. J Clin Invest (2014) 0.93
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. Eur J Cancer (2013) 0.92
High-dose extended-field irradiation and high-dose-rate brachytherapy with concurrent chemotherapy for cervical cancer with positive para-aortic lymph nodes. Int J Radiat Oncol Biol Phys (2009) 0.92
Cross-cultural application of the Korean version of the European Organization for Research and Treatment of Cancer quality of life questionnaire cervical cancer module. Oncology (2009) 0.92
A phase II study of neoadjuvant docetaxel plus doxorubicin (KBCS-01) in stage II, III breast cancer. Breast Cancer Res Treat (2006) 0.92
A comparison of cyclic variations in anterior knee laxity, genu recurvatum, and general joint laxity across the menstrual cycle. J Orthop Res (2010) 0.92
Comparison of temporary and permanent stent placement with concurrent radiation therapy in patients with esophageal carcinoma. J Vasc Interv Radiol (2005) 0.92
Unfavorable prognosis of small cell neuroendocrine carcinoma of the uterine cervix: a retrospective matched case-control study. Int J Gynecol Cancer (2010) 0.91